Safety of non-replicative and oncolytic replication-selective HSV vectors.

Autor: Epstein AL; EG 427 SAS, 29 Rue du Faubourg Saint Jacques, 75014 Paris, France. Electronic address: alberto@eg427.com., Rabkin SD; Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: rabkin@mgh.harvard.edu.
Jazyk: angličtina
Zdroj: Trends in molecular medicine [Trends Mol Med] 2024 Aug; Vol. 30 (8), pp. 781-794. Date of Electronic Publication: 2024 Jun 17.
DOI: 10.1016/j.molmed.2024.05.014
Abstrakt: Herpes simplex virus type 1 (HSV-1) is a DNA virus and human pathogen used to construct promising therapeutic vectors. HSV-1 vectors fall into two classes: replication-selective oncolytic vectors for cancer therapy and defective non-replicative vectors for gene therapy. Vectors from each class can accommodate ≥30 kb of inserts, have been approved clinically, and demonstrate a relatively benign safety profile. Despite oncolytic HSV (oHSV) replication in tumors and elicited immune responses, the virus is well tolerated in cancer patients. Current non-replicative vectors elicit only limited immune responses. Seropositivity and immune responses against HSV-1 do not eliminate either the vector or infected cells, and the vectors can therefore be re-administered. In this review we highlight vectors that have been translated to the clinic and host-virus immune interactions that impact on the safety and efficacy of HSVs.
Competing Interests: Declaration of interests A.L.E. is cofounder, chief scientific officer, and shareholder of EG 427 SAS. He is a coinventor on patents related to the use of replication-incompetent HSV-based vectors owned by the University of Versailles Saint Quentin (France) and EG 427. S.D.R. is a coinventor on patents relating to oncolytic HSVs that are owned and managed by Georgetown University and Massachusetts General Hospital, and which have received royalties from Amgen and ActiVec Inc. He is on the Scientific Advisory Board of EG 427 SAS, has received honoraria and equity, and has acted as a consultant and received honoraria from Replimune and Cellinta.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: